Adherence through cloud-based Personalised Treatment for Type 2 Diabetes

Adherence inhibits most T2D patients from reaching treatment targets. This impacts health, quality of life and cost society. To support care teams and empower patients to self-manage, we integrate data from continuous glucose monitors, connected insulin pens and activity trackers and provide real-time, personalised treatment guidance, data-derived insights, hypoglycemia warnings and dose reminders. Methods include large-scale data collection, development of a high-fidelity T2D model and required algorithms, and clinical feasibility testing of the full solution in a telemedicine context.

The consortium consists of:
Aalborg University
Steno Diabetes Center North Denmark
Steno Diabeter Center Zealand
Novo Nordisk
Glooko
Denmarks Technical University
University of Cambridge